NO993646L - Tiazolbenzensulfonamider som <beta>3-agonister for behandling av diabetes og fedme - Google Patents

Tiazolbenzensulfonamider som <beta>3-agonister for behandling av diabetes og fedme

Info

Publication number
NO993646L
NO993646L NO993646A NO993646A NO993646L NO 993646 L NO993646 L NO 993646L NO 993646 A NO993646 A NO 993646A NO 993646 A NO993646 A NO 993646A NO 993646 L NO993646 L NO 993646L
Authority
NO
Norway
Prior art keywords
compounds
levels
obesity
diabetes
treatment
Prior art date
Application number
NO993646A
Other languages
English (en)
Other versions
NO993646D0 (no
Inventor
Robert J Mathvink
Emma R Parmee
Samuel Tolman
Ann E Weber
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9705041.3A external-priority patent/GB9705041D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO993646D0 publication Critical patent/NO993646D0/no
Publication of NO993646L publication Critical patent/NO993646L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Tiazolsubstituerte benzen- sulfonamider er p3-adrenerge reseptor- agonister med meget liten pj- og P,- adrenerg reseptoraktivitet og forbind- elsene er som sådanne i stand til å øke lipolysen og energiforbruket i celler. Forbindelsene har således kraftig akti- vitet ved behandling av type II-diabet- BS og fedme. Forbindelsene kan også an- vendes for å nedsette triglyseridnivåer og kolesterolnivåer eller heve høy- densitetslipoproteinnivåer eller for å nedsette tarmmotilitet. I tillegg kan forbindelsene anvendes for å redusere neurogenisk inflammasjon eller som antidepressive midler. Forbindelsene fremstilles ved kopling av et amino- alkylfenylsulfonamid med et hensikts- messig substituert epoksid. Preparater og metoder for anvendelse av forbind- elsene ved behandling av diabetes og fedme og for nedsettelse av triglyse- ridnivåer og kolesterolnivåer, eller for heving av høydensitetslipoprotein- nivåer eller for redusering av tarm- motilitet, er også beskrevet.
NO993646A 1997-01-28 1999-07-27 Tiazolbenzensulfonamider som <beta>3-agonister for behandling av diabetes og fedme NO993646L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3676097P 1997-01-28 1997-01-28
GBGB9705041.3A GB9705041D0 (en) 1997-03-12 1997-03-12 Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity
PCT/US1998/001317 WO1998032753A1 (en) 1997-01-28 1998-01-23 THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Publications (2)

Publication Number Publication Date
NO993646D0 NO993646D0 (no) 1999-07-27
NO993646L true NO993646L (no) 1999-09-27

Family

ID=26311166

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993646A NO993646L (no) 1997-01-28 1999-07-27 Tiazolbenzensulfonamider som <beta>3-agonister for behandling av diabetes og fedme

Country Status (22)

Country Link
EP (1) EP0968209A1 (no)
JP (1) JP2001509166A (no)
KR (1) KR20000070568A (no)
CN (1) CN1251099A (no)
AR (1) AR011092A1 (no)
AU (1) AU728812B2 (no)
BG (1) BG103686A (no)
BR (1) BR9807096A (no)
CA (1) CA2278739A1 (no)
EA (1) EA199900692A1 (no)
EE (1) EE9900328A (no)
HR (1) HRP980044A2 (no)
HU (1) HUP0002053A3 (no)
ID (1) ID22273A (no)
IL (1) IL131130A0 (no)
IS (1) IS5131A (no)
NO (1) NO993646L (no)
PE (1) PE52299A1 (no)
PL (1) PL334833A1 (no)
SK (1) SK100099A3 (no)
TR (1) TR199902442T2 (no)
WO (1) WO1998032753A1 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
ATE385421T1 (de) 2000-01-21 2008-02-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
EP1258253A1 (en) * 2000-01-28 2002-11-20 Asahi Kasei Kabushiki Kaisha Novel remedies with the use of beta3 agonist
DK1138685T3 (da) 2000-03-31 2004-08-09 Pfizer Prod Inc Fremgangsmåde til fremstilling af substituerede pyridiner
CZ2003106A3 (cs) 2000-07-13 2003-04-16 Eli Lilly And Company Agonisté adrenergního beta-3 receptoru
US6498170B2 (en) * 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
DE60120748T2 (de) 2000-11-10 2007-05-16 Eli Lilly And Co., Indianapolis 3-substituierte oxindolderivate als beta-3-agonisten
CA2431171A1 (en) 2000-12-08 2002-06-13 Takeda Chemical Industries, Ltd. Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
AR035605A1 (es) 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
AR035858A1 (es) 2001-04-23 2004-07-21 Bayer Corp Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3
DE60208792T2 (de) * 2001-06-22 2006-08-31 Merck & Co., Inc. Tyrosin-kinase inhibitoren
JP2005507872A (ja) 2001-08-14 2005-03-24 イーライ・リリー・アンド・カンパニー ３−置換オキシインドールβ３アゴニスト
DE60215028T2 (de) 2001-08-14 2007-03-15 Eli Lilly And Co., Indianapolis Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
DE60208815T2 (de) * 2001-10-12 2006-07-20 Bayer Pharmaceuticals Corp., West Haven Phenyl substituierte 5-gliedrige stickstoff enthaltende heterocyclen zur behandlung von fettleibigkeit
ES2242890T3 (es) 2001-11-20 2005-11-16 Eli Lilly And Company Agonistas beta 3 de oxindol 3-sustituido.
WO2003044017A1 (en) 2001-11-20 2003-05-30 Eli Lilly And Company Beta 3 adrenergic agonists
US7009060B2 (en) 2002-01-11 2006-03-07 Eli Lilly And Company 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists
US6872724B2 (en) 2002-07-24 2005-03-29 Merck & Co., Inc. Polymorphs with tyrosine kinase activity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2006132196A1 (ja) * 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
CN102908350B (zh) 2005-09-14 2014-07-23 武田药品工业株式会社 用于治疗糖尿病的二肽基肽酶抑制剂
BRPI0616463A2 (pt) 2005-09-29 2011-06-21 Merck & Co Inc composto, composição farmacêutica, e, uso de um composto
EP1937264B1 (en) 2005-10-04 2011-06-08 Merck Sharp & Dohme Corp. Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence
EP2946778A1 (en) 2006-09-22 2015-11-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010047982A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
PT2531501E (pt) 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
EP2538784B1 (en) 2010-02-25 2015-09-09 Merck Sharp & Dohme Corp. Benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2677869B1 (en) 2011-02-25 2017-11-08 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
CA2898482A1 (en) 2013-02-22 2014-08-28 Linda L. Brockunier Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0091749A3 (en) * 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
US5451677A (en) * 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
HUP0002053A2 (hu) 2001-08-28
WO1998032753A1 (en) 1998-07-30
AU6038498A (en) 1998-08-18
HRP980044A2 (en) 1998-10-31
PL334833A1 (en) 2000-03-27
EA199900692A1 (ru) 2000-02-28
TR199902442T2 (xx) 2000-07-21
SK100099A3 (en) 2000-05-16
EE9900328A (et) 2000-02-15
AR011092A1 (es) 2000-08-02
BR9807096A (pt) 2000-04-18
CN1251099A (zh) 2000-04-19
ID22273A (id) 1999-09-23
IL131130A0 (en) 2001-01-28
EP0968209A1 (en) 2000-01-05
IS5131A (is) 1999-07-23
NO993646D0 (no) 1999-07-27
HUP0002053A3 (en) 2001-09-28
KR20000070568A (ko) 2000-11-25
CA2278739A1 (en) 1998-07-30
JP2001509166A (ja) 2001-07-10
PE52299A1 (es) 1999-05-26
AU728812B2 (en) 2001-01-18
BG103686A (bg) 2000-06-30

Similar Documents

Publication Publication Date Title
NO993646L (no) Tiazolbenzensulfonamider som &lt;beta&gt;3-agonister for behandling av diabetes og fedme
NO964548L (no) Substituerte sulfonamider som selektive 3 agonister for behandling av diabetes og fedme
DK0611003T3 (da) Substituerede phenylsulfonamider som selektive B3-agonister til behandlingen af diabetes og obesitet
Segal et al. Temperature-dependent physiological stability of rat skeletal muscle in vitro
BR0112409A (pt) Agonistas para beta3 adrenérgico
Kratz et al. Trends and results in tricuspid valve surgery
Rama et al. Papillary muscle approximation for ischemic mitral valve regurgitation
Vignola et al. New evidence of inflammation in asthma
Rabinowicz et al. Pathology of the capsular and synovial hip nerves in chronic hip diseases
Fisher Primary endocardial fibroelastosis: A review of 15 cases
Mittra et al. Follow-up of argon laser trabeculoplasty: is a day-one postoperative IOP check necessary?
Korntner et al. SELF-ASSEMBLED COLLAGEN-RICH CONSTRUCTS FOR TENDON ENTHESIS REPAIR
CAO et al. Land use and desertification in Horqin Sandy Land
ECSP982387A (es) Benceno sulfonamidas de tiazol como agonistas selectivos para el tratamiento de diabetes y obesidad
Madhav et al. THE COBB REPAIR AND ROSE OSTEOTOMY FOR STAGE II DYSFUNCTION OF TIBIALIS POSTERIOR TENDON
Quaranta et al. Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension
Lapidus et al. PROLONGED THROMBOPROPHYLAXIS WITH DALTEPARIN AFTER SURGICAL TREATMENT OF ACHILLES TENDON RUPTURE–A RANDOMIZED, PLACEBO-CONTROLLED STUDY.
Pons et al. HALLUX VALGUS: PROXIMAL CLOSING-WEDGE OSTEOTOMY OF THE FIRST METATARSAL. A REPORT ON 141 FEET.
Rosenthal et al. Stenting of systemic venous pathways after atrial repair for complete transposition
Espina Silva Carbohydrate-degrading enzymes from the thermophilic ethanologen Geobacillus thermoglucosidasius
Bjurstrom The porcine stress syndrome: An experimental study.
Chell ADOLESCENT HALLUX VALGUS
Block et al. New evidence based guidelines to manage atrial fibrillation
Cai et al. The structural response of muscle to limb lengthening
DK1456352T3 (da) Fast dyrkningssubstrat til mikroorganismer og eukaryote celler og fremgangsmåde til fremstilling deraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application